J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
This article was originally published in The Gray Sheet
Executive Summary
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.